List of Artificial Intelligence Companies in France - 39

Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

-Artificial Intelligence powered Drug Discovery. -a Biopharma company specialized in medicinal chemistry research of preclinical drug candidates. Ai-biopharma has in-silico solutions of Chemoinformatics, Molecular Modeling, Docking, Data analysis, SAR formatting/interpretation and also an Artificial Intelligence platform for the accelerated drug design towards the selection of new preclinical candidate drugs .

AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. We are growing and hiring! Check our career website: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA on our Welcome To The Jungle page: https://www.welcometothejungle.com/fr/companies/aqemia

Bioptimus is a developer of a universal AI foundation model designed to drive advancements in scientific research and biotechnological innovations. Their mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine.

Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply. Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development. We are currently envisaging clinical collaborations. Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.

CAPACITÉS is the subsidiary of University of Nantes, dedicated to the development of research. Specialized in engineering of innovative projects, CAPACITÉS exploits the latest scientific discoveries necessary for the performance of its customers. Springboard to differentiate in the ever-changing markets, areas of activity extend to technological and engineering sciences, human and social sciences and health. The activities of CAPACITÉS have advanced expertise on specific and cross-cutting themes. From idea generation to their implementation, CAPACITÉS impulse with its customers a strong value creation process through the development of R&D of high level dedicated to nine economic sectors.

Caranx Medical is a healthcare technology company based in Nice, France, founded by a team of experts including an entrepreneur, a clinician, and a researcher. The company focuses on enhancing access to less invasive medical care through innovative technologies. Its mission is to standardize complex surgical procedures, reduce risks associated with human error, and improve outcomes for patients and healthcare providers. The company specializes in developing intelligent robotic systems to improve surgical precision. One of its key products is the TAVIPILOT, a robotic solution designed for aortic valve procedures. Caranx Medical is also advancing the field with TAVIPILOT Soft, an AI software for real-time guidance during heart valve implantation, which is set for FDA submission in January 2025. The company has achieved significant milestones, including the world's first robotic-assisted heart valve implantation in an animal in April 2024. With a diverse team of over 20 professionals skilled in robotics, software management, and artificial intelligence, Caranx Medical is committed to driving innovation in interventional cardiology and improving patient care worldwide.

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform's features and data.

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

Pionner and leader in crop innovation software, since 1984, managing up to 250K agronomic trials per year. Doriane empowers your agronomy department in its digital transformation. Optimize your data, automate your workflows, and make agile decisions! We support innovation in agronomy—whether in the field, lab, or office—to tackle environmental, economic, and human challenges. We offer digital solutions to collect and enhance data for better decision-making. Our goal is to help agronomy teams adopt practices that are more effective, efficient, open, and resilient. Leverage our extensive experience in project management, technology complexity, cyber-security compliance, and evolving scientific knowledge. We bring our full ambition to every project, working closely with customer teams. Our Customer Success Service is fully engaged throughout the project lifecycle to ensure maximum user adoption. Choosing Doriane means more than just acquiring new software; it's embarking on a digital transformation journey with a partner who supports you at every stage to maximize your benefits. Bloomeo agro-testing software manages the evaluation of varieties, inputs, biosolutions, or practices with a systemic approach, emphasizing the environmental context of field data. Bloomeo BioSolutions evaluates the conditions under which a biosolution performs optimally. Bloomeo Product Development software supports product development activities in agronomy: aligning product design with market segments, managing multi-environment trials, standardizing data collection, and optimizing team collaboration. RnDExperience software supports all stages of the breeding process, from crossing to selection and evaluation. Our motto is “Agronomy driven by data!” and stakeholders worldwide appreciate making informed decisions based on meaningful information. Let's discuss your project: https://www.doriane.com/book-a-demo

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. It's going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldn't be a direct result of the surgeon's state of mind. We believe it's possible to create tools that will improve both patient outcome and surgeon experience. We believe it's unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europe's best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. We're all in. We're still hiring.

Created in 1990 and funded by AFM-TELETHON, Genethon, a pioneer in deciphering the human genome and identifying the genes associated with genetic diseases is today fully dedicated to the design and development of gene therapy treatments for rare diseases. At Genethon more than 180 scientists, clinicians and engineers specialized in gene therapy drug development, from research to the clinic, have joined forces in order to provide these innovative treatments to patients affected with rare disorders. These treatments also pave the way for new therapeutic approaches for frequent disorders.

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity. Please visit our webpage to know more about our products and offerings https://iktos.ai/products/

Climate change is the challenge of our generation. As innovators, we believe disruptive technology can bring performant solutions to the most dire challenges we face as a society. As we seek a more respectful way of living on our planet, nature itself has much to offer and teach us, starting with feeding the world of tomorrow with better nutrients - for animals, people and our planet - through insects. At Innovafeed, we are committed to inventing efficient technologies that reproduce Nature's processes on a large scale. By building a circular and zero waste agri-food chain replicating insect's role in nature, we want to reinvent our way of living with higher quality, sustainability and resilience, for everyone. We are a team of pragmatic dreamers who believe performance and positive impact can go hand in hand to reshape the world we leave to future generations.

Lumibird Medical is the medical division of the Lumibird Group, an expert in fiber lasers, solid lasers, laser diodes, and medical equipment. Formed from the 2020 merger of three entities – Quantel Medical, Ellex and Optotek – specializing in diagnostic and treatment devices for ophthalmology and other medical fields, our company is recognized for its commitment to innovation and stands out as a world leader in ophthalmic equipment. Our mission is to improve the comfort of patients worldwide by optimizing the standard of care with innovative diagnostic and treatment solutions dedicated to the medical sector. More information in our website!

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

Meddenovo offers a unique blend of AI technologies and molecular modeling to increase efficiency and success in drug development processes. Our technological platform, including bioAIM and focAlyze, delivers unparalleled drug candidate potency assessment and optimization of drug-like properties. In addition to designing small organic molecules, our proficiency in peptide-based medicine and metal chelators extends beyond traditional boundaries, offering a competitive advantage in creating solutions for novel drug research and development studies. In our integrated drug discovery services, we create a unique chemical space specific to your biological targets. We use our focAIyze module to explore druggability or any specific physiochemical property your project might need of the created chemical space. With our physics-based AI-supported software bioAIM, we screen the target with great accuracy. bioAIM, utilizing its unique blind docking capability, reveals precise binding sites and gauges the potency of molecules, ensuring compatibility with complex entities such as DNA or ribosomes. We also provide custom computational solutions using our modular tools to predict drug resistance bound to mutations, elucidate biochemical reaction mechanisms, and calculate metal affinity analysis. Meddenovo strives for precision and reliability in drug discovery, providing a refined approach to developing groundbreaking medicines with reduced failure rates and improved outcomes.

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).

At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health.

MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.

NETRI is a technology enabling company that provides human cell based smart assays for high throughput preclinical data acquisition for the neurological Pharma & Cosmetics industries. We provide organs-on-chip solutions & interoperable in vitro models designed to deeply accelerate drug discovery and preclinical trials by mimicking in vivo neural connectivity.

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers. Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic

AI in the service of precision medicine. We don't perform miracles, just create the tools that enable them. At Okeiro, we develop medical AI solutions that transform the monitoring of transplant patients and those with chronic conditions. Our predictive algorithms, scientifically validated digital biomarkers, convert complex medical data into information directly usable by healthcare teams. This technology allows us to: - Detect early signals of complications or graft rejection - Personalize each treatment for truly proactive care - Intervene before critical symptoms appear Our goal is clear: to tangibly improve patients' lives by equipping healthcare professionals with innovative tools that make a daily difference. In close collaboration with healthcare professionals and pharmaceutical companies, we accelerate the clinical validation of therapeutic innovations to make new treatments more quickly accessible to the patients who need them!

OPM is a technological company specialized in precision medicine. OPM's mission is to bring innovative therapeutic and diagnostic solutions to treat therapeutic resistance and metastasis evolution. The patient is at the centre of our reflexion, of our unique innovative model, and our investments. For OPM "our collective success is paramount", there can be no value creation without exchange, without dialogue. The value creation resulting for us from reciprocity, i.e. balanced and fair exchanges at all levels, whether between internal collaborators, or with our partners, therapists, patients, experts and investors. To discuss partnership or investment, don't hesitate to get in touch : info@oncodesign.com

One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences.

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

Qynapse is a neuroimaging technology company founded in 2015, originating from the CATI consortium of neuroimaging research laboratories. Based in France, with offices in the U.S. and Canada, Qynapse is dedicated to enhancing the diagnosis and monitoring of central nervous system (CNS) disorders, including Alzheimer’s disease, Multiple Sclerosis, and Parkinson’s disease. The company focuses on improving accuracy and reliability in clinical and research environments through AI-driven solutions. Qynapse offers proprietary AI-powered tools for analyzing neuroimaging data, such as MRI and PET scans. Its key product, QyScore®, features an automated platform with 20 algorithms and over 200 measures for assessing neurodegeneration and neuroinflammation. The company also provides clinical trial solutions that significantly reduce image-reading variability, enhancing trial efficiency, and normative datasets that deliver precise imaging metrics for tracking disease progression. Qynapse serves pharmaceutical and biotech companies, healthcare providers, and researchers, aiming to improve patient outcomes and accelerate drug development timelines.

Build the first Radiological Foundation Model Bring the radiological image to GPT Share the world's top medical expertise through AI Bring the best specialist to every patient/researcher/company

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Founded in 2017, SeqOne Genomics headquartered in Montpellier, France, is a fast-growing deep-tech company focused on turning genomic data into medically actionable insights in oncology, rare and inherited diseases. SeqOne clinical genomic analysis platform, powered by explainable AI, provides genomic labs and healthcare professionals with best-in-class accuracy, usability, and automation seamlessly across lab technologies. By streamlining complex multi-omics analysis workflows, we pave the way for a new era of personalized healthcare at scale, where genetic testing becomes as routine as traditional blood work, radically enhancing health outcomes for all. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.

Spotlight Medical is a precision medicine company striving to free all patients from cancer through a better understanding of each patient’s unique disease. We develop advanced AI tests that enhance treatment selection by leveraging decades of patient data. This ensures personalized and effective care for each individual, significantly improving patient outcomes and quality of life. By closely collaborating with physicians, we create impactful tests that address critical unmet clinical needs, opening a new era in cancer care. Founded in 2024, Spotlight Medical is backed by Institut Curie and Gustave Roussy, and has raised more than 6 million Euros to implement its first AI-driven test in clinical routine set to be announced soon.

Therapixel is a leading french software company specialized in artificial intelligence for medical imaging. Our aim is to develop a digital radiologist achieving the performance of best experts. Our AI is dedicated to breast cancer screening. That algorithm won the Digital Mammography DREAM Challenge, the largest Artificial Intelligence challenge ever organized. In its early years, Therapixel developed images visualization software for surgeons to make image access easier and faster from patient consultation to the operating room thanks to gesture control and intuitive user interfaces.

Cancer immunotherapy Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.

Tribun Health powers the digital transformation of cancer diagnosis by designing innovative solutions. These solutions enable the management, analysis and sharing of cellular images for both diagnostic laboratories and pharmaceutical/biotech companies. The company offers customized support in digital pathology, focused on the customer’s expectations. In the field of image analysis, our solutions are based on the latest innovations in terms of artificial intelligence, notably deep and machine learning algorithms. These tools support physicians and researchers in their diagnostic decision-making and scientific evaluation for the sake of patients. In the field of sharing, our solutions implement full web tools to support our customers in their telepathology, teaching or multi-centric clinical validation activities.

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta's DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters. The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation. VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space. Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.

Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks. Based on exhaustive datasets, the platform provides in-silico simulations to discover, and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies. Recognized for their contribution to advancing the field of gene and cell therapy, WhiteLab Genomics is part of the prestigious French government supported by French Tech 2030 program and recently joined the Bayer Co.Lab in Cambridge, MA, and Ginkgo Bioworks' Technology Network, marking major milestones in our international expansion.

Ziwig ® is a French company whose ambition is to improve women’s health through a holistic approach and the development of products, services and a care ecosystem guided by science and the unique biology of each individual. This approach is supported by ongoing research excellence and is based on the close collaboration of medical experts and engineers specialized in cutting- edge technologies such as artificial intelligence and Next Generation human RNA Sequencing. Its functioning is based on an ecosystem, driven by the quest for excellence and patient centered, that uses disruptive technologies. This contributes to the emergence of precision medicine that is individualized, predictive and participatory, serving women’s well-being and quality of life. Ziwig’s work has resulted in several publications that have appeared in international peer-reviewed scientific journals such as diagnostics, Nature scientific reports and Journal of Clinical Medicine. Follow us on Instagram : https://www.instagram.com/ziwigfrance/